Vericel Corporation (FRA:ATQP)

Market Cap	1.68B
Revenue (ttm)	220.50M
Net Income (ttm)	11.15M
Shares Out	n/a
EPS (ttm)	0.21
PE Ratio	150.36
Forward PE	94.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6
Open	34.60
Previous Close	34.40
Day's Range	34.60 - 34.60
52-Week Range	25.40 - 59.50
Beta	n/a
RSI	62.66
Earnings Date	Feb 27, 2026

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 357
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ATQP

Financial Performance

Financial numbers in USD